USPTO caves in on patent rules - but there were good reasons for change
This article was originally published in Scrip
Executive Summary
Last week the biopharmaceutical industry rejoiced when the US Patent and Trademark Office (USPTO), under its new head David Kappos, dropped its proposed patent rules limiting the number of times additional claims could be filed, which were designed to reduce the growing backlog of unexamined filings (see scripnews.com, October 12, 2009).